Sapphiros will use the funding to develop its molecular diagnostic platform for biothreat and emerging infectious disease detection in point-of-care settings.

The Alzheimer's Drug Discovery Foundation (ADDF) said on Monday that it has partnered with the Michael J. Fox Foundation (MJFF) to develop minimally invasive biomarkers for Parkinson's and Alzheimer's ...

Last week, readers were most interested in a story about Roche's blood-based IGRA test for latent TB getting CE marking.

Of the roughly 1 million disputes taken through the law's arbitration process in Q2 2025, around 129,000 were for lab codes, with payments for basic tests averaging hundreds of dollars.

Under the policy, blood-based tests may be eligible for coverage if they either are cleared or approved by the US FDA or measure phosphorylated-tau 217.

The firm said its long-term roadmap for the test includes addition of integrated, proprietary front-end automation in the future.

The firm began its early-access program in breast cancer in March and is now expanding the test's indications to include colorectal and renal cancers.

The updated test showed 80 percent sensitivity for detecting colorectal cancer overall and 18 percent sensitivity for advanced precancerous lesions.

The test, along with other research-use tests for neurodegenerative disease, run on the Danaher subsidiary's DxI 9000 Immunoassay Analyzer system.

The project, which is an initiative of the Quest Diagnostics Foundation, aims to expand healthcare access in the area, including through no-cost laboratory testing.

The platform, including the assay, specimen collection kit, and associated software, underwent a comprehensive review including evidence of analytical and clinical validity.